Updates in prognostication and treatment of Waldenström's macroglobulinemia

Research output: Contribution to journalReview article

Abstract

Waldenström's macroglobulinemia (WM)is a rare, incurable hematologic disorder with a relatively indolent course in a majority of the patients. Despite this, a significant proportion of patients require treatment because of hypersecretion of immunoglobulin M and the invasion of bone marrow and peripheral organs by neoplastic lymphoplasmacytic lymphoma cells. Historically, there has been a dearth of research and therapeutic advancements in the field of WM, with most understanding based on other, related B-cell lymphoid malignancies, including multiple myeloma, chronic lymphocytic leukemia, and non-Hodgkin lymphoma. Recently, there has been an increase in dedicated work to better explain the pathobiology of WM, which has identified several clinical and genetic markers that serve to prognosticate disease course and patient outcomes. Furthermore, this has led to dedicated clinical trials and the development of novel drugs/regimens including the first Food and Drug Administration-approved agent for this diagnosis, ibrutinib. This review aims to document some of the recent advancements with respect to prognostic markers and therapeutic options for patients with WM, as well as certain selected novel treatments with unique mechanisms of action, that are currently under development.

Original languageEnglish (US)
JournalHematology/ Oncology and Stem Cell Therapy
DOIs
StatePublished - Jan 1 2019

Fingerprint

Waldenstrom Macroglobulinemia
B-Cell Chronic Lymphocytic Leukemia
Therapeutic Human Experimentation
United States Food and Drug Administration
Therapeutics
Multiple Myeloma
Genetic Markers
Non-Hodgkin's Lymphoma
Immunoglobulin M
Lymphoma
B-Lymphocytes
Biomarkers
Bone Marrow
Clinical Trials
Pharmaceutical Preparations
Neoplasms

Keywords

  • Prognosis
  • Survival
  • Treatment
  • Waldenström's macroglobulinemia

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

@article{e6d435da6f3c4e34a0380bbc506f7142,
title = "Updates in prognostication and treatment of Waldenstr{\"o}m's macroglobulinemia",
abstract = "Waldenstr{\"o}m's macroglobulinemia (WM)is a rare, incurable hematologic disorder with a relatively indolent course in a majority of the patients. Despite this, a significant proportion of patients require treatment because of hypersecretion of immunoglobulin M and the invasion of bone marrow and peripheral organs by neoplastic lymphoplasmacytic lymphoma cells. Historically, there has been a dearth of research and therapeutic advancements in the field of WM, with most understanding based on other, related B-cell lymphoid malignancies, including multiple myeloma, chronic lymphocytic leukemia, and non-Hodgkin lymphoma. Recently, there has been an increase in dedicated work to better explain the pathobiology of WM, which has identified several clinical and genetic markers that serve to prognosticate disease course and patient outcomes. Furthermore, this has led to dedicated clinical trials and the development of novel drugs/regimens including the first Food and Drug Administration-approved agent for this diagnosis, ibrutinib. This review aims to document some of the recent advancements with respect to prognostic markers and therapeutic options for patients with WM, as well as certain selected novel treatments with unique mechanisms of action, that are currently under development.",
keywords = "Prognosis, Survival, Treatment, Waldenstr{\"o}m's macroglobulinemia",
author = "Pooja Advani and Aneel Paulus and Sikander Ailawadhi",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.hemonc.2019.05.002",
language = "English (US)",
journal = "Hematology/ Oncology and Stem Cell Therapy",
issn = "1658-3876",
publisher = "King Faisal Specialist Hospital and Research Centre",

}

TY - JOUR

T1 - Updates in prognostication and treatment of Waldenström's macroglobulinemia

AU - Advani, Pooja

AU - Paulus, Aneel

AU - Ailawadhi, Sikander

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Waldenström's macroglobulinemia (WM)is a rare, incurable hematologic disorder with a relatively indolent course in a majority of the patients. Despite this, a significant proportion of patients require treatment because of hypersecretion of immunoglobulin M and the invasion of bone marrow and peripheral organs by neoplastic lymphoplasmacytic lymphoma cells. Historically, there has been a dearth of research and therapeutic advancements in the field of WM, with most understanding based on other, related B-cell lymphoid malignancies, including multiple myeloma, chronic lymphocytic leukemia, and non-Hodgkin lymphoma. Recently, there has been an increase in dedicated work to better explain the pathobiology of WM, which has identified several clinical and genetic markers that serve to prognosticate disease course and patient outcomes. Furthermore, this has led to dedicated clinical trials and the development of novel drugs/regimens including the first Food and Drug Administration-approved agent for this diagnosis, ibrutinib. This review aims to document some of the recent advancements with respect to prognostic markers and therapeutic options for patients with WM, as well as certain selected novel treatments with unique mechanisms of action, that are currently under development.

AB - Waldenström's macroglobulinemia (WM)is a rare, incurable hematologic disorder with a relatively indolent course in a majority of the patients. Despite this, a significant proportion of patients require treatment because of hypersecretion of immunoglobulin M and the invasion of bone marrow and peripheral organs by neoplastic lymphoplasmacytic lymphoma cells. Historically, there has been a dearth of research and therapeutic advancements in the field of WM, with most understanding based on other, related B-cell lymphoid malignancies, including multiple myeloma, chronic lymphocytic leukemia, and non-Hodgkin lymphoma. Recently, there has been an increase in dedicated work to better explain the pathobiology of WM, which has identified several clinical and genetic markers that serve to prognosticate disease course and patient outcomes. Furthermore, this has led to dedicated clinical trials and the development of novel drugs/regimens including the first Food and Drug Administration-approved agent for this diagnosis, ibrutinib. This review aims to document some of the recent advancements with respect to prognostic markers and therapeutic options for patients with WM, as well as certain selected novel treatments with unique mechanisms of action, that are currently under development.

KW - Prognosis

KW - Survival

KW - Treatment

KW - Waldenström's macroglobulinemia

UR - http://www.scopus.com/inward/record.url?scp=85066507950&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066507950&partnerID=8YFLogxK

U2 - 10.1016/j.hemonc.2019.05.002

DO - 10.1016/j.hemonc.2019.05.002

M3 - Review article

AN - SCOPUS:85066507950

JO - Hematology/ Oncology and Stem Cell Therapy

JF - Hematology/ Oncology and Stem Cell Therapy

SN - 1658-3876

ER -